Relapsed B cell precursor Acute lymphoblastic leukemia

Also known as: Relapsed B-cell precursor Acute Lymphoblastic Anemia

DrugDrug NameDrug Description
DB09052BlinatumomabAn antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD).
DB15699Brexucabtagene autoleucelA modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
DB05889Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
DB13881TisagenlecleucelA CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.
DrugDrug NamePhaseStatusCount